4 research outputs found

    Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2)

    Get PDF
    With interest we read the paper by Juste et al 1 proposing the amount of zymogen-granule membrane glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn\u27s disease (CD) marker. Indeed, a decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls. GP2 is a homologue to the urinary Tamm–Horsefall protein demonstrating an antimicrobial function by binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that are partaking in immune responses against such microbes.2 GP2 is overexpressed in the inflamed intestine of patients with CD and has an immunomodulating role in innate and acquired immune responses.3 ,4Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD.4 Altogether, these findings indicate two major GP2 sources (pancreatic/intestinal) and support a role for GP2 in the interaction between the immune system and intestinal microbiota.3 Thus, loss of tolerance to GP2 could play a role in CD\u27s pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by Juste et al 1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by a higher prevalence of bacteria with poor or no GP2 binding in patients with CD

    Tierexperimentelle Untersuchungen zu antioxidativen Enzymen und Hitzeschockproteinen als endogene Schutzsysteme bei Herzinsuffizienz

    Get PDF
    Gesteigerter oxidativer Stress ist ein typisches Zeichen in der Pathogenese der Herzinsuffi-zienz. Anhand von 2 Rattenmodellen sollen charakteristische Veränderungen des enzymatischen antioxidativen Systems, repräsentiert durch die Glutathionperoxidase (GSH-Px) und Superoxiddismutase (SOD) sowie Änderungen im Hitzeschockproteinsystem (Hsp) untersucht werden, für das stellvertretend Hsp25 und Hsp72 bestimmt wurden. Daneben wurde die Lipidperoxidation durch die Konzentration von Thiobarbitursäure-reaktiven Substanzen (TBARS) quantifiziert. Im ersten Rattenmodell, der Hypertonie-induzierten Herzinsuffizienz durch permanente Renin-Angiotensin-System-Aktivierung in doppelt transgenen Ratten konnte eine linksventrikuläre Hypertrophie mit CK-Isoenzym-Shift mit vermehrter Expression von CK-MB und -BB beobachtet werden. Es kam in beiden Ventrikeln der transgenen Tiere zu einer Zunahme der Lipidperoxidation begleitet von einer Erniedrigung der Serum-Vitamin E-Konzentration durch Verbrauch. SOD und Hsp72 blieben unverändert. Durch die biventrikuläre Zunahme der GSH-Px-Aktivität bei linksventrikulär erhöhtem Hsp25-Gehalt konnte die Toleranz gegenüber Hypoxie/Reoxygenierungsstress erhöht werden. In der 2. Teilstudie - der Myokardinfarkt-induzierten Herzinsuffizienz - wurden die Parameter oxidativer Schädigung und antioxidativen Schutzes im Akutstadium (14-16h) und 3, 6 und 9 Wochen nach experimentellem Infarkt (MI) bestimmt. In der Akutphase zeigten sich in beiden Ventri-keln und im Papillarmuskel gesteigerte GSH-Px- und SOD-Aktivitäten, ohne dass kardiale Hypertrophie vorlag. Hsp72 und Hsp25 waren während der Akutphase nach MI im Papillar-muskel und im linken Ventrikel erhöht. In der Folge resultiert eine verbesserte kontraktile Funktion bei experimentellem Hypoxie/Reoxygenierungsstress. Damit gelang es erstmals eine Selbstprotektion des Myokards während eines akuten MI nachzuweisen. Erst ab der 6. Woche trat kardiale Hypertrophie auf, begleitet vom charakteristischen CK-Isoenzym-Shift. Während die SOD und die Hitzeschockproteine nach der akuten Phase auf das Niveau der Kontrollen absanken, blieb die hohe GSH-Px-Aktivität im linken Ventrikel über den gesamten Untersuchungszeitraum bestehen, bei zunehmender Toleranz des Herzens gegenüber Hypoxie/Reoxygenierungsstress. Die vorgelegten tierexperimentellen Untersuchungen zeigen, dass das Herz sowohl unter akut als auch unter chronisch gesteigertem oxidativen Stress Mechanismen zur Selbstprotektion aktivieren kann, die eine Prävention bzw. Minimierung von Schädigungsreaktionen durch Sauerstoffradikale ermöglichen.Elevated oxidative stress is typical in the pathogenesis of heart failure. Characteristical changes in antioxidant enzyme status, represented by glutathionperoxidase (GSH-Px) and superoxide dismutase (SOD), and changes in heat shock protein status (Hsp), denoted by Hsp25 and Hsp72, have been revealed in two different rat-models. Lipidperoxidation was quantified by the concentration of thiobarbituric acid reactive substances (TBARS). In the first model of heart failure caused by permanent activation of renin-angiotensin system in double transgenic rat, leftventricular hypertrophy accompanied by a shift of creatine kinase (CK) isoenzyme pattern to higher concentration of fetale CK-MB an -BB-isoforms was found. Higher TBARS concentrations and lower alpha-tocopherol levels caused by consumption have been measured. SOD and Hsp72 remained unchanged. The tolerance against experimental hypoxia/reoxygenation was improved by higher levels of GSH-Px and Hsp25 in both right and left ventricular tissue. In the second study of heart failure caused by experimental myocardial infarction (MI) the parameters of oxidant demolishing and antioxidant defence were evaluated under acute condi-tions (14-16h) and 3, 6 and 9 weeks after infarction. In the acute period higher activities of GSH-Px and SOD in non-hypertrophied left and right ventricular tissue and papillary muscle have been reported. Leftventricular and papillary muscle Hsp25 and Hsp72 content showed higher levels 14-16 hours after MI compared with controls, improving the contractile function in hypoxia/reoxygenation experiments. These findings suggest for the first time a myocardial self-protection after acute myocardial infarction. 6 and 9 weeks after MI leftventricular hyper-trophy occurred attended by the characteristic CK-isoenzymeshift. While SOD-activity and Hsp-content decreased to the levels of the controls, GSH-Px remained on higher altitude in leftventricular tissue in all examined periods after MI. This was accompanied by better toler-ance against hypoxia/reoxygenation stress. These findings of experimental-induced heart failure show the activation of myocardial self protecting mechanisms under acute and chronic oxidative stress conditions, minimizing or even preventing demolishing reactions of oxygen radicals

    Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2)

    No full text
    With interest we read the paper by Juste et al 1 proposing the amount of zymogen-granule membrane glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn's disease (CD) marker. Indeed, a decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls. GP2 is a homologue to the urinary Tamm–Horsefall protein demonstrating an antimicrobial function by binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that are partaking in immune responses against such microbes.2 GP2 is overexpressed in the inflamed intestine of patients with CD and has an immunomodulating role in innate and acquired immune responses.3 ,4Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD.4 Altogether, these findings indicate two major GP2 sources (pancreatic/intestinal) and support a role for GP2 in the interaction between the immune system and intestinal microbiota.3 Thus, loss of tolerance to GP2 could play a role in CD's pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by Juste et al 1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by a higher prevalence of bacteria with poor or no GP2 binding in patients with CD.This article is from Gut 64 (2015): 517–519, doi:10.1136/gutjnl-2014-307854. Posted with permission.</p
    corecore